We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Millennium Initiates Two Phase Il Trials of Aurora A Kinase Inhibitor
News

Millennium Initiates Two Phase Il Trials of Aurora A Kinase Inhibitor

Millennium Initiates Two Phase Il Trials of Aurora A Kinase Inhibitor
News

Millennium Initiates Two Phase Il Trials of Aurora A Kinase Inhibitor

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Millennium Initiates Two Phase Il Trials of Aurora A Kinase Inhibitor"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Millennium Pharmaceuticals, Inc., announced that Millennium has initiated two Phase II clinical trials of MLN8237.

The first trial will examine the molecule in adult patients with aggressive non-Hodgkin’s lymphoma (NHL), while the second trial will evaluate the drug in patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). MLN8237 is an oral, selective Aurora A kinase inhibitor discovered and developed by Millennium scientists.

“We are very excited to begin these studies examining MLN8237 in several hematologic malignancies,” said Nancy Simonian, M.D., Chief Medical Officer, Millennium. “This novel target is the latest drug candidate in our expanded oncology pipeline to enter Phase II clinical trials and helps move Millennium and Takeda toward the goal of becoming a global oncology leader.”

Both trials will be open-label, multi-center trials for patients with relapsed or refractory aggressive NHL, AML and MDS. Endpoints to be examined include response rates, time to progression and safety and tolerability. These trials are the first of a broader Phase II program examining the use of MLN8237 in both solid tumors and hematologic malignancies. An additional study is ongoing with the Children’s Oncology Group examining MLN8237 in pediatric neuroblastoma.
Advertisement